Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06131840 · ClinicalTrials.gov registry record · Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Recruiting
Registry status
Phase 1
Development phase
914
Enrollment target
20
Study locations

NCT06131840: Recruiting Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

NCT06131840 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 914 participants, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06131840, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
914 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.

Primary Outcome

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Conditions Studied

Carcinoma, Non-Small Cell Lung Pancreatic Ductal Adenocarcinoma Colorectal Neoplasms Gastroesophageal Junction Adenocarcinoma Small Cell Lung Carcinoma Stomach Neoplasms

Interventions

  • DRUG 5-Fluorouracil (5-FU)
  • DRUG Oxaliplatin
  • DRUG PF-08046050
  • DRUG bevacizumab
  • DRUG Leucovorin (LV)

Study Locations (20)

Arizona

  • Mayo Clinic Hospital - Phoenix
  • Mayo Clinic - Scottsdale

California

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
  • IP Address: City of Hope Investigational Drug Services(IDS) - Duarte

Colorado

  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
  • University of Colorado Hospital - Aurora

Florida

  • Florida Cancer Specialists - Orlando
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando

Maryland

  • Sidney Kimmel Comprehensive Cancer at Johns Hopkins - Baltimore
  • The Johns Hopkins University - Baltimore

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Beth Israel Deaconess Medical Center - Boston

Minnesota

  • Mayo Clinic Cancer Center - Rochester
  • Mayo Clinic - Rochester

Tennessee

  • Sarah Cannon Research Institute - Pharmacy - Nashville
  • SCRI Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 914 participants
Start Date 2023-11-20
Est. Completion 2030-09-12
Phase Phase 1
Seagen, a wholly owned subsidiary of Pfizer

28 total trials

What NCT06131840 shows while recruiting

NCT06131840 is an interventional study that assigns participants to a tested intervention. The registered 914 participants enrollment target is mid-sized for trials with a published cap, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (188% higher).

The record links to 6 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which 5-Fluorouracil (5-FU) is the first listed.

NCT06131840 names 20 study sites across 11 states, led by Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06131840 about?

NCT06131840 is a clinical study titled "A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors". This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts o...

What is the current status of trial NCT06131840?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 914 participants. The study started on 2023-11-20. Estimated completion is 2030-09-12.

What conditions does trial NCT06131840 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Pancreatic Ductal Adenocarcinoma, Colorectal Neoplasms, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma.

What interventions are being tested in trial NCT06131840?

The interventions under investigation include: 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (DRUG), PF-08046050 (DRUG), bevacizumab (DRUG), Leucovorin (LV) (DRUG).

Who is sponsoring clinical trial NCT06131840?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06131840 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06131840's enrollment target sits among peer trials

914 9th of 130 higher than 122 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05739955 · 918 participants · NA

    Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms

  • NCT06216548 · 909 participants · NA

    E-PRIME For Children With Medical Complexity

  • NCT04589845 · 920 participants · Phase 2

    Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

  • NCT06109870 · 920 participants · NA

    Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06131840

Source: ClinicalTrials.gov NCT06131840, the US trial registry maintained by the National Library of Medicine. NCT06131840 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.